

24 October 2023

Botanix Pharmaceuticals signs exclusive agreement with leading telehealth provider UpScriptHealth®

Key points

- Botanix has signed an exclusive agreement with UpScriptHealth® to provide the digital platform and telehealth services for the commercial launch of *Sofdra*™ (sofpironium bromide) gel, 15%
- The agreement with UpScriptHealth is an important step towards building the commercial infrastructure for the successful launch of *Sofdra* following approval
- With more than 1 million patients served, UpScript is the leading digital platform for pharmaceutical companies to offer medications and other therapeutics direct to consumers
- For patients who are actively seeking support and solutions online, UpScript provides a fast, convenient, clickable option

Philadelphia and Phoenix US, 24 October 2023: [Botanix Pharmaceuticals](#) (ASX:BOT) has signed an exclusive agreement with UpScriptHealth® to provide the digital platform and telehealth services for the commercial launch of *Sofdra*™ (sofpironium bromide) gel, 15%. The agreement with UpScriptHealth is an important step towards building the commercial infrastructure for the successful launch of *Sofdra* following approval.

UpScriptHealth® was the first company to deliver prescriptions online. With more than 1 million patients served, UpScript is the leading digital platform for pharmaceutical companies to offer medications and other therapeutics direct to consumers.

The UpScript website will be the first point of entry for the majority of patients seeking a prescription for *Sofdra* gel. Patients will be matched with UpScript's nationwide network of licensed U.S. physicians for online consultations. If a physician finds that a patient is an appropriate candidate, an electronic prescription will be issued and forwarded to a pharmacy that fills it and then ships it to the customer's home or office.

For patients who are actively seeking support and solutions online, UpScript provides a fast, convenient, clickable option.

Botanix CEO, Dr Howie McKibbon said: "Our exclusive agreement with UpScriptHealth® forms a cornerstone of the commercial infrastructure required for the successful launch of *Sofdra*™ (sofpironium bromide) gel, 15%. UpScriptHealth's proven digital platform and telehealth services are expected to greatly facilitate *Sofdra* prescriptions.

"UpScript will provide a fast, convenient, clickable option for patients seeking hyperhidrosis solutions online. Botanix and our patients will benefit from the enhanced patient access offered by UpScript's digital hub."

In coming weeks, Botanix also plans to finalize arrangements with its pharmacy partners as well as other service providers, that will ultimately comprise the commercial infrastructure required to successfully launch *Sofdra*™ post approval.

Release authorised by the Board of Directors.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which is progressing its lead product Sofpironium Bromide for the treatment of primary axillary hyperhidrosis, through FDA approval. FDA issued a Complete Response Letter for the product in late 3Q CY2023 focused on validating revised Instructions For Use and the Company is currently planning for a resubmission of the NDA in 1Q2024 with approval targeted for mid-CY2024. Sofpironium Bromide is positioned to be a leading first line and second line therapy and potentially represents a safe and effective new option for patients.

The Company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea (successful Phase 1b/2 study in 4Q 2022), dermatitis and acne respectively. Botanix is also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications
Botanix Pharmaceuticals
P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett
WE Communications
P: +61 450 648 064

hhowlett@we-worldwide.com

Media enquiries

Haley Chartres
H^CK
P: +61 423 139 163

haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs, the Company's ability to obtain marketing approvals for its product candidates, the expected timing and/or results of regulatory approvals and the outcome and effects of Sofpironium Bromide and the market for Sofpironium Bromide. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update

these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

For personal use only